$27.15 Million in Sales Expected for Paratek Pharmaceuticals

Wall Street brokerages expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) to post sales of $27.15 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Paratek Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $27.00 million and the highest estimate coming in at $27.30 million. Paratek Pharmaceuticals reported […]

Related Keywords

, Paratek Pharmaceuticals , Zacks Investment Research , Paratek Pharmaceuticals Inc , Nasdaq , Cubist Systematic Strategies , Paratek Pharmaceuticals Company Profile Get Rating , Citigroup Inc , Campbell Co Investment Adviser , Wall Street , Get Rating , Paratek Pharmaceutical , Investment Research , Systematic Strategies , Summit Global Investments , Pharmaceuticals Company Profile , Nasdaq Prtk , Prtk , Medical , 89354m10 , Ratings , Consensus ,